1 / 1

Endo Pharmaceuticals: Leaders in Pain Management Solutions

Endo Pharmaceuticals Holdings Inc., established in 1920, specializes in developing innovative branded and generic treatments for various pain conditions. With flagship products like the Lidoderm patch and Percocet, Endo addresses chronic, acute, and neuropathic pain. They recently obtained marketing rights for new migraine therapies and have several products in clinical development aimed at providing effective solutions. With approximately 1000 employees and a strong financial profile, Endo is committed to enhancing patient care and expanding its presence in the pain management market.

mari-solis
Download Presentation

Endo Pharmaceuticals: Leaders in Pain Management Solutions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chadds Ford, PA www.endo.com • Therapeutic Areas • Pain- Chronic • Pain- Acute • Pain- Neuropathic • Neurology, Oncology Company Description - Endo Pharmaceuticals Holdings Inc was established in 1920 as a specialty pharmaceutical company focused on developing branded and generic treatments for pain. Flagship products include the Lidoderm patch and Percocet. In July 2004, Endo obtained exclusive rights to market Vernalis‘ [menstrually associated] migraine therapy, frovatriptan. They currently hold the rights to commercialize EpiCept’s LidoPAIN BP for acute low back pain, and have 8 products in clinical development. Endo’s 2006 sales were $909.7M USD. The company currently has approximately 1000 employees. Transaction Rationale– Endo seeks & PPC can provide: Additional validated pain products for a primarily late stage pipeline. Secondary indications may be of interest to Endo, as they are looking to expand into related markets. PPC seeks & Endo can provide: US presence and access to US stock exchange, Phase II & III products, experience developing topical analgesic treatment, strong financial position. 5 June 2007 Confidential

More Related